Advanced techniques for penetration enhancement in transdermal drug delivery system

Current Drug Delivery

Volumn 8, Issue 4, 2011, Pages 456-473

  Swain, Suryakanta ^a   Beg, Sarwar ^a   Singh, Astha ^a   Patro, Ch Niranjan ^a   Rao, M E Bhanoji ^a  

^a ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

CHADD; Iontophoresis; Liquipatch; Medicated tattoos; Metered dose transdermal spray; Needle free injection; Photomechanical waves; Regulatory consideration; WEDD

Indexed keywords

ADRENALIN PLUS LIDOCAINE; ALCOHOL; BOTULINUM TOXIN A; BOVINE SERUM ALBUMIN; CALCEIN; DESMOPRESSIN; ERYTHROPOIETIN; ESTRADIOL; GRANISETRON; HEPARIN; INSULIN; INTERFERON; LIDOCAINE; OLIGONUCLEOTIDE; OVALBUMIN; OXYBUTYNIN; PENETRATION ENHANCING AGENT; PLASMID DNA; PROGESTERONE; PROPRANOLOL; QUININE; RECOMBINANT GROWTH HORMONE; SALICYLIC ACID; TESAMORELIN; TESTOSTERONE; TITANIUM; TRIPTORELIN; UNINDEXED DRUG; VACCINE; VAPREOTIDE; VITAMIN B GROUP;

AEROSOL; BIODEGRADABILITY; BLADDER DISEASE; BLADDER HYPERTROPHY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; ELECTRIC MODEL; ELECTRODYNAMIC; ELECTROOSMOSIS; ELECTROPORATION; HEAT; HEAT ABLATION; HUMAN; IN VITRO STUDY; IONTOPHORESIS; LASER; MEMBRANE PERMEABILITY; MENOPAUSAL SYNDROME; METERED DOSE TRANSDERMAL SPRAY; MICROFABRICATED MICRONEEDLE; MICROINJECTION; MICROPORATION; MOLECULE; NANOFABRICATION; NEEDLE; NONHUMAN; PAIN; PARTICLE SIZE; PHOTOACOUSTIC SPECTROSCOPY; PHOTOMECHANICAL WAVE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SKIN; SKIN ABRASION; SYRINGE; THERMODYNAMICS; TRANSDERMAL PATCH; ULTRASOUND; VELOCITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; SKIN ABSORPTION;

EID: 79959326450     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111795767979     Document Type: Review

References (171)

1. Rizwan, M.; Aqil, M.; Talegaonkar, S.; Azeem, A.; Sultana, Y.; Ali, A. Enhanced transdermal drug delivery techniques: an exten sive review of patents. Recent Pat. Drug Deliv. Formul., 2009, 3(2), 105-124.
2. Garala, K.; Faldu, N.; Basu, B.; Bhalodia, R.; Mehta, K.; Joshi, B. Chemical penetration enhancement: A review. J. Pharm. Res., 2009, 2(12), 1804-1808.
3. Sugino, M.; Todo, H.; Sugibayashi, K. Skin permeation and transdermal delivery systems of drugs: history to overcome barrier function in the stratum corneum. Yakugaku Zasshi, 2009, 129(12), 1453-1458.
4. Higo N. Recent trend of transdermal drug delivery system development. Yakugaku Zasshi, 2007, 127(4), 655-662.
5. Nino, M.; Calabro, G.; Santoianni, P. Topical delivery of active principles: the field of dermatological research. Dermatol. Online J., 2010, 16(1), 4.
6. Guy, R.H.; Hadgraft, J. Transdermal drug delivery, Marcel Dekker: New York, 2003.
7. Prausnitz, M.R.; Mitragotri, S.; Langer, R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov., 2004, 3,115-124.
8. Hampton, T. Breaking barriers in transdermal drug delivery. J. Am. Med. Assoc., 2005, 293, 2083.
9. Sugino, M.; Todo, H.; Sugibayashi, K. Skin permeation and transdermal delivery systems of drugs: history to overcome barrier function in the stratum corneum. Yakugaku Zasshi, 2009, 129(12), 1453-1458.
10. Benson, H.A.E. Transdermal drug delivery: Penetration enhancement techniques. Curr. Drug Deliv., 2005, 2(1), 23-33.
11. Flynn, G.L. In: Percutaneous absorption; Bronaugh, R.L.; Maibach, H.I., Eds.; Marcel Dekker Inc.: New York, 1985; pp. 17-52.
12. Potts, R.O., Guy, R.H. Predicting skin permeability. Pharm. Res.,1992, 9(5), 663-669.
13. Barry, B. In: The science of dosage forms design; Aulton, E. M., Ed.; Harcourt publishers, Churchill Livingstone: Newyork, 2002; Vol. 2, pp. 499-533.
14. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev., 2004, 56, 603-618.
15. Barry, B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci., 2001, 14, 101-114.
16. Gordon, R.D.; Peterson, T.A. Four myths about transdermal drug delivery. Drug Deliv. Technol., 2003, 3(4).
17. Shah, V.P. In: Transdermal drug delivery system regulatory requirements (USA). In: Conference on to and thru the skin, Eds.; IPA-AAPS-FIP-APSTJ, Mumbai, India, February 20-21, 2009.
18. Jones, S.A. Evolution of transdermal drug delivery: Recent progress in active drug delivery technologies has helped miniature, powerful device to generate required clinical responses. http://www.pharmaquality.com (Accessed September 20, 2010).
19. Cross, S.E.; Roberts, M.S. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development. Curr. Drug Deliv., 2004, 1, 81-92.
20. McAllister, D.V.; Wang, P.M.; Davis, S.P.; Park, J.H.; Canatella, P.J.; Allen, M.G.; Prausnitz, M.R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc. Natl. Acad. Sci. USA, 2003, 100(24), 13755-13760.
21. Prausnitz, M.R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev., 2004, 56(5), 581-587.
22. McAllister, D.V.; Allen, M.G., Prausnitz, M.R. Microfabricated microneedles for gene and drug delivery. Annu. Rev. Biomed. Eng., 2000, 2, 289-313.
23. Reed, M.L; Lye, W.K. Microsystems for drug and gene delivery. Proc. IEEE, 2004, 92, 56-75.
24. Gill, H.S.; Prausnitz, M.R. Coated microneedles for transdermal delivery. J. Control. Release, 2007, 117, 227-237.
25. Prausnitz, M.R.; Allen, M.G.; Gujral, I.J. Microneedle drug delivery device. U.S. Patent 6,611,707, August 26, 2003.
26. Gerstel, M.S; Place, V.A. Drug delivery device. U.S. Patent 3,964,482, June 22, 1976.
27. Trautman, J.; Wong, P.S.; Daddona, P.E.; Kim, H.L.; Zuck, M.G. Device for enhancing transdermal agent flux. U.S. Patent 6,322,808, November 27, 2001.
28. Lin, L.; Pisano, A.P. Silicon-processed microneedles. J. Microelec-tromech. Syst., 1999, 8, 78-84.
29. Papautsky, I.; Brazzle, J.; Swerdlow, H.; Weiss, R.; Frazier, A.B. Micromachined pipette arrays. IEEE Trans. Bioned. Eng., 2000, 47, 812-819.
30. Gardeniers, J.G.E.; Luttge, R.; Berenschot, J.W. Silicon micro-machined hollow microneedles for transdermal liquid transport. J. MEMS., 2003, 6, 855-862.
31. Ito, Y.; Yoshimitsu, J.; Shiroyama, K. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J. Drug Target., 2006, 14, 255-261.
32. Chen, J.; Wise, K.D.; Hetke, J.F.; Bledsoe Jr, S.C. A multichannel neural probe for selective chemical delivery at the cellular level. IEEE Trans. Biomed. Eng., 1997, 44, 760-769.
33. Talbot, N.H.; Pisano, A.P. Polymolding: two wafer polysilicon micromolding of closed-flow passages for microneedles and micro-fluidic devices. Tech. Dig. Solid-State Sensor and Actuator Workshop, 1998, 265-268.
34. Zahn, J.D.; Talbot, N.H.; Liepmann, D.; Pisano, A.P. Microfabri-cated microdialysis microneedles for minimally invasive biomedi-cal devices. Biomed. Microdevice, 2000, 2, 295-303.
35. Fukushima, K.; Ito, Y.; Ishihata, M.; Sugioka, N.; Takada, K. Insulin micropiles comprising biodegradable polymers for production of a long-term hypoglycemic effect. J. Drug Target., 2010, [Epub ahead of print].
36. Fukushima, K.; Yamazaki, T.; Hasegawa, R.; Ito, Y.; Sugioka, N.; Takada, K. Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. Diabetes Technol. Ther., 2010, 12(6), 465-474.
37. Chen, B.; Wei, J.; Tay, F.E.H.; Wong, Y.T.; Iliescu, C. In: Silicon microneedles array with biodegradable tips for transdermal drug delivery. Stresa, Italy, 25-27 April 2007, DTIP.
38. Ito, Y.; Yamazaki, T.; Sugioka, N.; Takada, K. Self-dissolving micropile array tips for percutaneous administration of insulin. J. Mater. Sci. Materials. Med. 2009, 21(2), 835-841.
39. Fukushima, K.; Ise, A.; Morita, H.; Hasegawa, R.; Ito, Y.; Sugioka, N.; Takada, K. Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. Pharm. Res., (2010) [Eupub ahead of print].
40. Park, J.H. Biodegradable polymer microneedles: Fabrication, mechanics and. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2004, 4, 2654-2657.
41. Lee, J.W.; Park, J.H.; Prausnitz, M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials, 2008, 29(13), 2113-2124.
42. Gittard, S.D.; Ovsianikov, A.; Chichkov, B.N.; Doraiswamy, A.; Narayan, R.J. Two-photon polymerization of microneedles for transdermal drug delivery. Expert Opin. Drug Deliv., 2010, 7(4), 513-533.
43. ® microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res., 2002, 19(1), 63-70.
44. ®) technology. Pharm. Res., 2001, 18(12), 1789-1793.
45. Sinha, V.R.; Bhinge, J.R.; Trehan, A. Transdermal, transcutaneous and topical delivery. Express Pharma Pulse, March 3, 2005.
46. Bryan, J. Transdermal drug delivery may be a common technique in the future. The Pharma. J., 2004, 273, 292-293.
47. ® transdermal technology development for the delivery of therapeutic peptides & proteins. Drug Deliv. Tech., 2002, 2(5), 54-57.
48. ®) technology. Pharm. Res., 2001, 18, 1789-1793.
49. Rathbone, M.J.; Hadgraft, J.; Roberts, M.S. Modified release drug delivery technology, Marcel Dekker: New York, 2004, 126, 471-619.
50. Morgan, T.M.; Sullian, H.; Reed, B.L.; Finnin, B.C. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J. Pharm. Sci., 1998, 87, 1226-1228.
51. Finnin, B.C.; Morgan, T.M. Transdermal penetration enhancers: applications, limitations, and potential. J. Pharm. Sci., 1999, 88, 955-958.
52. Marie-Laure, L.; Herve, R.; Patrick, W.; Richard, H.G. Formulation and evaluation of testosterone transdermal spray. J. Pharm. Sci., 2006, 95, 1693-1702.
53. Humberstone, A.; Evans, A.M.; Davis, S.R. A comparative study of the pharmacokinetics of testosterone (T) following administration of a metered-dose transdermal spray (MDTS) to the abdomen or forearm in healthy postmenopausal women with low serum testosterone. In: Proceedings of the Endocrine Society's 85th Annual Meeting, Philadelphia, June 19-22, 2003.
54. ® as a possible future contraceptive. Contraception, 2007, 76(6), 432-438.
55. Morton, T.L.; Gattermeir, D.J.; Petersen, C.A., Day, W.W.; Schumacher, R.J. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. J. Clin. Pharmacol., 2010, 49(7), 1037-1046.
56. Bakshi, A.; Bajaj, A.; Malhotra, G.; Madan, M.; Amrutiya, N. A novel metered dose transdermal spray formulation for oxybutynin. Ind. J. Pharm. Sci., 2008, Nov-Dec, 733-739.
57. Green, P.G.; Flanagan, M.; Shroot, B.; Guy, R.H. In: Physical skin penetration enhancement, Walters, K.A.; Hadgraft. J. Eds.; Marcel Dekker Inc.: New York, 1993, pp. 311-333.
58. Green, P.G. Iontophoretic delivery of peptide drugs. J. Control. Release, 1996, 41(1-2), 33-48.
59. Kanikkannan, N. Iontophoresis-based transdermal delivery systems. Bio Drugs, 2002, 16(5), 339-347.
60. Dixit, N.; Bali, V.; Baboota, S.; Ahuja, A.; Ali, J. Iontophoresis-An approach for controlled drug delivery: A review. Curr. Drug De-liv., 2007, 4, 1-10.
61. ® delivery by iontophoresis. Brit. J. Dermatol., 2004, 151, 1093-1095.
62. Sage, B.H. In: Encyclopedia of pharmaceutical technology, Swar-brick, J.; Boylan, J.C., Eds.; Marcel Dekker Inc.: New York, 1993, Vol. 8, pp. 217-247.
63. Banga, A.K.; Bose, S.; Ghosh, T.K. Iontophoresis and electropora-tion: comparisons and contrasts. Int. J. Pharm., 1999, 179(1), 1-19.
64. Kalia, Y.N.; Naik, A.; Garrison, J.; Guy, R.H. Iontophoretic drug delivery. Adv. Drug Deliv. Rev., 2004, 56(5), 619-58.
65. Wang, Y.; Thakur, R.; Fan, Q.; Michniak, B. Transdermal iontophoresis: combination strategies to improve transdermal iontopho-retic drug delivery. Eur. J. Pharm. Biopharm., 2005, 60(2), 179-191.
66. Kirjavainen, M.; Urtti, A.; Monkkonen, J.; Hirvonen, J. Influence of lipids on the mannitol flux during transdermal iontophoresis in vitro. Eur. J. Pharm. Sci., 2000, 10(2), 97-102.
67. Marro, D.; Kalia, Y.N.; Delgado-Charro, M.B.; Guy, R.H. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm. Res., 2001, 18(12), 1701-1708.
68. Schuetz, Y.B.; Naik, A.; Guy, R.H.; Vuaridel, E.; Kalia, Y.N. Transdermal iontophoretic delivery of triptorelin in vitro. J. Pharm. Sci., 2005, 94(10), 2175-2182.
69. Schuetz, Y.B.; Naik, A.; Guy, R.H.; Vuaridel, E.; Kalia, Y.N. Transdermal iontophoretic delivery of vapreotide acetate across porcine skin in vitro. Pharm. Res., 2005, 22(8), 1305-1312.
70. Cazares-Delgadillo, J.; Ganem-Rondero, A.; Quintanar-Guerrero, D.; Lopez-Castellano, A.C.; Merino, V.; Kalia, Y.N. Using trans-dermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. Eur. J. Pharm. Sci., 2010, 39(5), 387-393.
71. Volpato, N.M.; Santi, P.; Colombo, P. Iontophoresis enhances the transport of acyclovir through nude mouse skin by electrorepulsion and electroosmosis. Pharm. Res., 1995, 12(11), 1623-1627.
72. Hirvonen, J.; Guy, R.H. Transdermal iontophoresis: modulation of electroosmosis by polypeptide. J. Control. Release, 1998, 50(1-3), 283-289.
73. Li, G.L.; Danhof, M.; Bouwstra, J.A. Lontophoretic delivery of apomorphine in vitro: physicochemic considerations. Pharm. Res., 2001, 18(11), 1509-1513.
74. KiranVaka, S.R.; Shivakumar, H.N.; Murthy, S.N. Constant voltage 'Irontophoresis. Pharm. Dev. Technol., 2010. [Eupub ahead of print].
75. Sammeta, S.M.; Vaka, S.R.; Murthy, S.N. Transdermal drug delivery enhanced by low voltage electropulsation (LVE). Pharm. Dev. Technol., 2009, 14(2), 159-164.
76. Curdy, C.; Kalia, Y.N.; Guy, R.H. Non-invasive assessment of the effects of iontophoresis on human skin in-vivo. J. Pharm. Pharmacol., 2001, 53, 769-777.
77. Chaturvedula, A.; Joshi, D.P.; Anderson, C.; Morris, R.L.; Sem-browich, W.L.; Banga, A.K. In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. Int. J. Pharm., 2005, 297(1-2), 190-196.
78. Dolly, J.O. Therapeutic and research exploitation of botulinum neurotoxin. Eur. J. Neurol., 1997, 4, S5-S10.
79. Shelley, W.B.; Talanin, N.Y.; Shelley, E.D. Botulinum toxin therapy for palmar hyperhidrosis. J. Am. Acad. Dermatol., 1998, 38, 227-229.
80. Power, I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br. J. Anaesth., 2007, 98(1), 4-11.
81. Menon, G.K.; Kollias, N.; Doukas, A.G. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J. Invest. Dermatol., 2003, 121, 104-109.
82. Doukas, A.G.; Flotte, T.J. Physical characteristics and biological effects of laser-induced stress waves. Ultrasound Med. Biol., 1996, 22(2), 151-164.
83. Lee, S.; Doukas, A.T.J. Laser-generated stress waves and their effects on the cell membrane. Select Topics Quant. Electron., 1999, 5, 997-1003.
84. McAulife, D.J.; Lee, S.; Flotte, T.J.; Doukas, A.G. Stress-wave-assisted transport through the plasma membrane in vitro. Laser Surg. Med., 1997, 20, 216-222.
85. Mulholland, S.E.; Lee, S.; McAulife, D.J.; Doukas, A.G. Cell loading with laser-generated stress waves. The role of stress gradient. Pharm. Res., 1999, 16, 514-518.
86. Soughayer, J.S.; Krasieva, T.; Jacobson, S.C., Ramsey, J.M., Tromberg, B.J.; Allbritton, N.L. Characterization of cellular op-toporation with distance. Anal. Chem., 2000, 72, 1342-1347.
87. Soukos, N.S.; Socransky, S.S.; Mulholland, S.E.; Lee, S.; Doukas, A.G. Photomechanical drug delivery into bacterial biofilms. Pharm. Res., 2000, 17, 405-409.
88. Lee, S.; Anderson, T.; Zhang, H.; Flotte, T.J.; Doukas, A.G. Alteration of cell membrane by stress waves in vitro. Ultrasound Med. Biol., 1996, 22, 1285-1293.
89. Lee, S.; Kollias, N.; McAuliffe, D.J.; Flotte, T.J.; Doukas, A.G. Topical drug delivery with a single photomechanical wave. Pharm. Res., 1999, 16(11), 1717-1721.
90. Hofmann, G.A. In: Methods in Molecular Medicine; Jaroszeski, M.J.; Heller, R.; Gilbert, R, Eds.; Humana Press, Totowa, NJ, 2000, pp. 37-61.
91. Charoo, N.A.; Rahman, Z.; Repka, M.A.; Murthy, S.N. Electropo-ration: An avenue for transdermal drug delivery. Curr. Drug Deliv. 2010, 7(2), 125-136.
92. Prausnitz, M.R.; Bose, V.G.; Langer, R.; Weaver, J.C. Electropora-tion of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. USA, 1993, 90, 10504-10508.
93. Pliquett, U.; Langer, R.; Weaver, J.C. Changes in the passive electrical properties of human stratum corneum due to electroporation. Biochim. Biophys. Acta, 1995, 1239, 111-121.
94. Lombry, C.; Dujardin, N.; Preat, V. Transdermal delivery of mac-romolecules using skin electroporation. Pharm. Res., 2000, 17(1), 32-37.
95. Tokudome, Y.; Sugibayashi, K. The effects of calcium chloride and sodium chloride on the electroporation-mediated skin permeation of fluorescein isothiocyanate (FITC)-dextrans in vitro. Biol. Pharm. Bull., 2003, 26(10), 1508-1510.
96. Sen, A.; Zhao, Y.L.; Hui, S.W. Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys. J., 2002, 83(4), 2064-2073.
97. Sen, A.; Daly, M.E.; Hui, S.W. Transdermal insulin delivery using lipid enhanced electroporation. Biochim. Biophy. Acta, 2002, 1564(1), 5-8.
98. Bommannan, D.; Tamada, J.; Leung, L.; Potts, R.O. Effect of elec-troporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharm. Res., 1994, 11, 1809-1814.
99. Vanbever, R.; Lecouturier, N.; Preat, V. Transdermal delivery of metoprolol by electroporation. Pharm. Res., 1994, 11, 1657-1662.
100. Prausnitz, M.R.; Edelman, E.R.; Gimm, J.A.; Langer, R.; Weaver, J.C. Transdermal delivery of heparin by skin electroporation. Bio-technol., 1995, 13, 1205-1209.
101. Zewert, T.E.; Pliquett, U.F.; Langer, R.; Weaver, J.C. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun., 1995, 212, 286-292.
102. Vanbever, R.; LeBoulenge, E.; Preat, V. Transdermal delivery of fentanyl by electroporation I. Influence of electrical factors. Pharm. Res., 1996, 13, 559-565.
103. Jadoul, A.; Preat, V. Electrically-enhanced transdermal delivery of domperidone. Int. J. Pharm., 1997, 154, 229-234.
104. Chen, T.; Langer, R.; Weaver, J.C. Skin electroporation causes molecular transport across the stratum corneum through localized transport regions. J. Investig. Dermatol. Symp. Proc., 1998, 3(2), 159-165.
105. Vaughan, T.E.; Weaver, J.C. In: Methods in molecular medicine; Jaroszeski, M.J.; Heller, R.; Gilbert, R., Ed.; Human Press, Inc., Totowa, NJ, 2000, Vol. 37, pp. 187-211.
106. Benga, A.K.; Bose, S.; Ghosh, T. K. Iontophoresis and electropora-tion: comparisions and contrasts. Int. J. Pharm., 1999, 179(1), 1-19.
107. Wallace, MS.; Ridgeway, B.; Jun, E.; Schulteis, G.; Rabussay, D.; Zhang, L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: an evaluation of skin anesthesia. Reg. Anesth. Pain Med., 2001, 26, 229-238.
108. Zhang, L.; Li, L.; Hoffmann, GA.; Hoffman, RM. Depth targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases. Biochem. Biophy. Res. Comm., 1996, 220, 633-636.
109. Wong, T.W.; Zhao, Y.L.; Sen, A.; Hui, S.W. Pilot study of topical delivery of methotrexate by electroporation. Br. J. Dermatol., 2005, 152(3), 524-530.
110. Daud, A.I.; DeConti, RC.; Andrews, S.; Urbas, P.; Riker A.I.; Sondak, V.K.; Munster, P.N.; Sullivan, D.M.; Ugen, K.E.; Messina, J.L.; Heller, R. Phase I Trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol., 2008, 26(36), 5896-5903.
111. Larkin, J.O.; Collins, C.G.; Aarons, S.; Tangney, M.; Whelan, M.; O'Reily, S.; Breathnach, O.; Soden, D.M.; ÒSullivan, G.C. Electro-chemotherapy: aspects of preclinical development and early clinical experience. Ann. Surg., 2007, 245(3), 469-479.
112. Larkin, J.O.; Collins, C.G.; Aarons, S.; Tangney, M.; Whelan, M.; ÒReily, S.; Breathnach, O.; Soden, D.M.; ÒSullivan, G.C.; Elec-trochemotherapy: aspects of preclinical development and early clinical experience. Ann. Surg., 2010, 251(4), 773.
113. Singh, T.R.; Garland, M.J.; Cassidy, C.M.; Migalska, K.; Demir, Y.K.; Abdelghany, S.; Ryan, E.; Woolfson, A.D.; Donnelly, R.F. Microporation techniques for enhanced delivery of therapeutic agents. Recent Pat. Drug Deliv. Formul. 2010, 4(1), 1-17.
114. Bramson, J.; Dayball, K.; Evelegh, C.; Wan, Y.H.; Page, D.; Smith, A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene The., 2003, 10, 251-260.
115. Eppstein, Jonathan, A. Multiple Mechanical Microporation of Skin or Mucosa. U.S. Patent 6,183,434, February 6, 2001.
116. Banga, A.K.; Microporation applications for enhancing drug delivery, Expert Opin. Drug Deliv., 2009,6(4), 343-354.
117. Bachhav, Y.G.; Heinrich, A.; Bragagna, T.; Boehler, C.; Strohal, R.; Kalia, Y.N. Using laser microporation to increase transdermal delivery of imiquimod. AAPS., 2009.
118. Eppstein, J.A. Method and Apparatus for Enhancing Flux Rates of a Fluid in a Microporated Biological Tissue. U.S patent 6,173,202, January 09, 2001.
119. Akther, P.; Banga, A.K. Transdermal delivery of insulin from polymer matrices using microporation technology. PhD Thesis, 1584, Septmber 2007.
120. Bachhav, Y.G.; Summer, S.; Heinrich, A.; Bragagna, T.; Bohler, C.; Kalia, Y.N. Effect of controlled laser microporation on drug transport kinetics into and across the skin. J. Control. Release, 2010, 146(1), 31-36.
121. Pikal, M.J. The role of electroosmotic flow in transdermal iontophoresis. Adv. Drug Deliv. Rev., 1992, 9, 201-237.
122. Phipps, J.B., Gyory, J.R. Transdermal ion migration. Adv. Drug Deliv. Rev., 1992, 9, 137-176.
123. Riviere, J.E.; Heit, M.C. Electrically assisted transdermal drug delivery. Pharm. Res., 1997, 14(6), 687-697.
124. Nair, V.; Panchagnula, R. Physicochemical considerations in the iontophoretic delivery of a small peptide: in vitro studies using ar-ginine vasopressin as a model peptide. Pharmacol. Res., 2003, 48(2), 175-182.
125. Tang, H.; Wang, C.J.; Blankschtein, D.; Langer, R. An investigation of the role of cavitation in low frequency ultrasound-mediated transdermal drug transport. Pharm. Res., 2002, 19, 1160-1169.
126. Mitragotri, S.; Kost, J. Transdermal delivery of heparin and low-molecular weight heparin using low-frequency ultrasound. Pharm. Res., 2001, 18, 1151-1156.
127. Smith, N.B. Perspectives on transdermal ultrasound mediated drug delivery. Int. J. Nanomedicine, 2007, 2(4), 585-594.
128. Terahara, T.; Mitragotri, S.; Langer, R. Porous resins as a cavita-tion enhancer for low-frequencey sonophoresis. J. Pharm. Sci., 2002, 91, 753-759.
129. Park, E.J.; Dodds, J.; Smith, N.B. Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection. Int. J. Nanomedicine, 2008, 3(3), 335-341.
130. Le, L.; Kost, J.; Mitragotri, S. Synergistic effect of ultrasound and iontophoresis on transdermal drug delivery: Applications to heparin delivery. Pharm. Res., 2000, 17(9), 1151-1154.
131. Hikima, T.; Ohsumi, S.; Shirouzu, K.; Tojo, K. Mechanisms of synergistic skin penetration by sonophoresis and iontophoresis. Biol. Pharm. Bull., 2009, 32(5), 905-909.
132. Jones, D.R. Use of iontophoresis or electrotherapy and ultrasound to deliver agents for skin rejuvenation. U.S. Patent 20090246270, 2009.
133. Denet, A.R.; Ucakar, B.; Preat, V. Transdermal delivery of timolol and atenolol using electroporation and iontophoresis in combination: a mechanistic approach. Pharm. Res., 2003, 20(12), 1946-1951.
134. Dakowicz, A.; Latosiewicz, R. The value of iontophoresis combined with ultrasound in patients with the carpal tunnel syndrome. Rocz. Akad. Med. Bialymst., 2005, 50(Suppl 1), 196-198.
135. Shetty, S.; Moore, T.L.; Jackson, S.; Brettle, D.; Herrick, A.L. A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis. Rheumatology, 2005, 44, 536-538.
136. Prausnitz, M. Reversible skin permeabilization for transdermal delivery of macromolecules. Crit. Rev. Ther. Drug Carrier Syst., 1997, 14, 455-483.
137. Kost, J.; Pliquett, U.; Mitragotri, S.; Yamamoto, A.; Weaver, J.; Langer, R. Enhanced transdermal delivery: synergistic effect of ultrasound and electroporation. Pharm. Res., 1996, 13, 633-638.
138. Wells, D.J. Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo. Cell Biol. Toxicol., 2009, 26(1), 21-28.
139. Bommanon, D.; Tamada, J.; Leung, L.; Potts, R. Effects of electro-poration on transdermal iontophoretic delivery of leutinizing hormone releasing hormone. Pharm. Res., 1994, 11, 1809-1814.
140. Chang, S.; Hofmann, G.; Zhang, L.; Deftos, L.; Banga, A. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J. Control. Release, 2000, 66, 127-133.
141. Lvovich, V.F.; Matthews, E.; Riga, A.T.; Kaza, L. AC electroki-netic platform for iontophoretic transdermal drug delivery. J. Control. Release, 2010, 145(2), 134-140.
142. Fang, J.Y.; Sung, K.C.; Wang, J.J.; Chu, C.C.; Chen, K.T. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J. Pharm. Pharmacol., 2002, 54(10), 1329-1337.
143. Hirsch, A.C.; Upasani, R.S.; Banga, A.K. Factorial design approach to evaluate interactions between electrically assisted enhancement and skin stripping for delivery of tacrine. J. Control. Release, 2005, 103(1), 113-121.
144. Badkar, A.V.; Smith, A.M.; Eppstein, J.A.; Banga, A.K. Transder-mal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm. Res., 2007, 24(7), 1389-1395.
145. Sieg, A.; Guy, R.H.; Delgado-Charro, M.B. Electroosmosis in transdermal iontophoresis: implications for noninvasive and calibration-free glucose monitoring. Biophys. J., 2004, 87, 3344-3350.
146. Santi, P.; Guy, R.H. Reverse iontophoresis-parameters determining electroosmotic flow: I. pH and ionic strength. J. Control. Release, 1996, 38, 159-165.
147. Santi, P.; Guy, R.H. Reverse iontophoresis-parameters determining electroosmotic flow: II. Electrode chamber formulation. J. Control. Release, 1996, 42, 29-36.
148. Wong, T.W.; Chen, C.H.; Huang, C.C.; Lin, C.D.; Hui, S.W. Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J. Control. Release, 2006, 110(3), 557-565.
149. Yan, K.; Todo, H.; Sugibayashi, K. Transdermal drug delivery by in-skin electroporation using a microneedle array. Int. J. Pharm., 2010, 397(1-2), 77-83.
150. Zhao, Y.L.; Murthy, S.N.; Manjili, M.H., Guan, L.J.; Sen, A.; Hui, S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine, 2006, 24(9), 1282-1290.
151. Daugimont, L.; Baron, N.; Vandermeulen, G.; Pavselj, N.; Mik-lavcic, D.; Jullien, M.C.; Cabodevila, G.; Mir, L.M.; Preat, V. Hollow Microneedle arrays for intradermal drug delivery and DNA electroporation. J. Membr. Biol. 2010, 236, 117-125.
152. Levy, A. Advances in disposable needle free injector technology. Innovations Pharm. Sci., 100-109, http://www.iptonline.com/arti-cles/public/IPTFIVE100NP.pdf. (Accessed September 20, 2010).
153. Houser, T.A.; Joseph, G.; Brad, J.; Thomas, J.; Dachrit, N.; Eileen, L.; Frank, K. Effectiveness of transdermal, needle-free injections for reducing pork carcass defects. Meat Science, 2004, 68, 329-332.
154. Stachowiak, J.C.; Marcio, G.; Thomas, H.; Laleh, J.; Sapun, H.; Daniel, A. Piezoelectric control of needle-free transdermal drug delivery. J. Control. Release, 2007, 124, 88-97.
155. Giudice, E.L.; James, D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev., 2006, 58, 68-89.
156. Brown, M.B.; Martin, G.P.; Jones, S.A.; Akomeah, F.K. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv., 2006, 13(3), 175-187.
157. Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Nat. Bio-technol., 2008, 26, 1261-1268.
158. Brown, M.B.; Traynor, M.J.; Martin, G.P.; Akomeah, F.K. Trans-dermal drug delivery systems: Skin perturbation devices. Methods Mol. Biol., 2008, 437, 119-139.
159. Roberts, M.S. Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease. Clin. Exp. Pharmacol. Physiol., 1997, 24(11), 874-879.
160. Stachowiak, J.C.; Marcio, G.; Thomas, H.; Laleh, J.; Sapun, H.; Daniel, A. Piezoelectric control of needle-free transdermal drug delivery. J. Control. Release, 2007, 124, 88-97.
161. Herdon, T.O.; Salvador, G.; Gowrishankar, T.R.; Rox, A.; James, C. Transdermal microconduits by microscission for drug delivery and sample acquisition. BMC Med., 2004, 2(12), 1-11.
162. Zhang, J.; Zhang, H.; Hull, W.A.; Rigby, L. Integrated apparatus for controlled heat aided dermal drug delivery. U.S. Patent 6,546,281. April 8, 2003.
163. Anon. CHADD (Controlled-Heat Assisted Drug Delivery). http://www.zars.com/chadd.html (Accessed July 7, 3005)
164. The future of drug delivery is here. Teikoku Pharma USA. http://www.teikokuusa.com/tpu_brochure.pdf. (Accessed September 28, 2010).
165. Deluccia, R.J. MacroChem: Transitioning from drug delivery to specialty pharmaceuticals. Drug Deliv. Technol., 2004, 4(2).
166. Sinha, V.R.; Bhinge, J.R.; Trehan, A. Transdermal, transcutaneous and topical delivery. Express Pharma Pulse. http://www.express-pharmaonline.com/20050303/technologytrendz01.shtml. (Accessed September 28, 2010).
167. Gomez, C.; Costela, A.; Garcia-Moreno, I.; Llanes, F.; Teijon, J.M.; Blanco, D. Laser treatments on skin enhancing and controlling transdermal delivery of 5-fluorouracil. Laser Surg. Med., 2008, 40, 6-12.
168. Stanton, Jr.; Vincent, P. Tumor necrosis factor receptor 2. U.S. Patent 6673908, January 1, 2004.
169. th Annual Meeting, San Francisco, CA, USA, March 11-15, 2000.
170. Kalia, Y.N. Transdermal drug delivery system: Clinical aspects. Dermatol. Invest., 1998, 16(2), 289-299.
171. Shah, V.P. In: Transdermal drug delivery; Guy, R.H.; Hadgraft, J., Eds.; Marcel Dekker Inc., Informa Health care, USA, 2002.